FFCD - Pembrolizumab in combination with CAPOX and bevacizumab in patients with microsatellite stable (MSS) metastatic colorectal cancer and a high immune infiltrate: preliminary results of FFCD 1703 POCHI trial

Pembrolizumab in combination with CAPOX and bevacizumab in patients with microsatellite stable (MSS) metastatic colorectal cancer and a high immune infiltrate: preliminary results of FFCD 1703 POCHI trial

Auteurs

David Tougeron, J.F. Emile, A. Bodere, E. Barbier, J. Bez, L.M. Dourthe, H. Perrier, S.Corbinais, V. Le Brun-Ly, K. Bideau, B. Chibaudel, F. Khemissa, J. Hartwig, M.Laly, A. Lievre, C. Toullec, M. Muller, P. Laurent-Puig, C. Lepage, J. Taieb

Journal / Conférence

ESMO

Type de publication

Communication Orale

Etude

FFCD 1703 POCHI

Localisation

Colorectal